In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Cyberonics, Inc.

http://www.cyberonics.com/

Latest From Cyberonics, Inc.

Deals Shaping the Medical Industry, January 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2016.

Deals BioPharmaceutical

SweetBio Inc.

To enhance the healing process following tooth loss and produce better outcomes after subsequent bone grafts, SweetBio Inc. has developed a dissolvable membrane that contains a small amount of medical-grade Manuka honey. This honey comes from New Zealand and contains the compound MgO, which has been found to have wound healing, antimicrobial and antibacterial properties.

Medical Device

Device/Diagnostics Quarterly Deal Statistics, Q1 2013

Device companies kicked off 2013 by raising $1.1 billion via 45 transactions; the only device M&A transaction in Q1 to exceed the billion-dollar mark was Cardinal Health Inc.’s $2.07 billion acquisition of AssuraMed. Diagnostics firms began 2013 by raising a total of $286 million in the opening quarter, a 46% improvement over Q4 2012’s tally.

Medical Device Deals

Cleave Gains Further Validation From Investors With Addition Of $10M To Its Series A

The California biotech proves that an early-stage company can be just as attractive to investors as a proof-of-concept biotech if the science is strong.

BioPharmaceutical North America
See All

Company Information

  • Other Names / Subsidiaries
    • LivaNova
UsernamePublicRestriction

Register